130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
"HIV Preventive Vaccine" [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects
Condition: HIV Infections
Intervention: Biological: HIV-1 Peptide Immunogen, Multivalent
3 Unknown  Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1-infected Mothers
Conditions: HIV-1;   HIV Infections
Intervention: Biological: MVA.HIVA
4 Completed Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP
5 Active, not recruiting Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad26.ENVA.01 (rAd26);   Biological: Placebo Vaccine
6 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA009-00-VP;   Biological: VRC-HIVADV014-00-VP
7 Completed Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
8 Completed Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
9 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
10 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1 and A244 rgp120/HIV-1;   Biological: QS-21;   Biological: rgp120/HIV-1MN
11 Completed Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV (vCP205)
12 Completed A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN
13 Completed HIV-1 Vaccine Test in Uninfected Adult Volunteers
Conditions: Healthy;   HIV Seronegativity
Intervention: Drug: VRC4302
14 Completed Safety of and Immune Response to a DNA HIV Vaccine Followed By an Adenoviral Vector HIV Vaccine in Healthy Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP placebo;   Biological: VRC-HIVADV014-00-VP placebo
15 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults
Condition: HIV Infections
Intervention: Biological: rgp120/HIV-1MN
16 Completed A Phase I Safety and Immunogenicity Study of HIV p17/p24:Ty-VLP in HIV-1 Seronegative Subjects
Condition: HIV Infections
Interventions: Biological: HIV p17/p24:Ty-VLP;   Biological: Aluminum hydroxide
17 Completed An Investigational Combination Vaccine Given to People Who Are Not Infected With HIV
Condition: HIV Infections
Interventions: Biological: Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A;   Biological: NefTat;   Drug: AS02A Adjuvant;   Biological: gp120W61D
18 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
19 Completed Safety of and Immune Response to an Adenoviral HIV Vaccine (VRC-HIVADV014-00-VP) With or Without a Plasmid HIV Vaccine (VRC-HIVDNA016-00-VP) in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC-HIVADV014-00-VP;   Biological: VRC-HIVDNA016-00-VP
20 Completed Early Immune Responses to Vaccination - A Substudy to HVTN 205
Condition: HIV Infections
Interventions: Biological: JS7 DNA vaccine;   Biological: MVA/HIV62 vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years